Pfizer Inc. announced today that the European Commission approved updates to the Summary of Product Characteristics for the companyA's pneumococcal conjugate vaccine Prevenar 13* , regarding its use in certain populations at high risk of pneumococcal disease.
http://www.pmpnews.com/news/pfizer-receives-european-approval-label-update-regarding-use-prevenar-13-certain-high-risk-po-0
http://www.pmpnews.com/news/pfizer-receives-european-approval-label-update-regarding-use-prevenar-13-certain-high-risk-po-0
No comments:
Post a Comment